Last updated 15 days ago
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
230 patients around the world
Available in Colombia, Brazil, United States, Argentina
Hoffmann-La Roche
5Research sites
230Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
Recruiting
Hospital Provincial del Centenario - Rosario, Santa Fe
Recruiting
Fundación CENIT para la Investigación en Neurociencias
Recruiting
Instituto de Oncología de Rosario - IOR
Recruiting
Centro Oncológico Korben
Recruiting
StudyINAVO122
SponsorHoffmann-La Roche
Conditions
Breast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05894239
